Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7F2VG)

• Drug Name: SA-237 Drug Info
• Synonyms: Second generation IL-6 antagonist (mAb, inflammatory disease), Chugai

Indication

Disease Entry	ICD 11	Status	REF
Encephalopathy	8E47	Phase 3	[1]
Neuromyelitis optica	8A43	Phase 3	[2]
Rheumatoid arthritis	FA20	Phase 3	[3]

• Cross-matching ID: TTD Drug ID: DM7F2VG

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin 6 receptor (IL6R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tocilizumab	DM7J6OR	Giant cell arteritis	4A44.2	Approved	[5]
Sarilumab	DMOGNXY	Rheumatoid arthritis	FA20	Approved	[6]
Sirukumab	DMK8AQP	Cutaneous lupus erythematosus	EB5Z	Phase 3	[7]
SAR153191	DMXAO4J	Ankylosing spondylitis	FA92.0	Phase 3	[8]
Vobarilizumab	DM9KNJT	Rheumatoid arthritis	FA20	Phase 2	[9]
ALX-0061	DMO1VHC	Autoimmune diabetes	5A10	Phase 2	[10]
SBP-002	DM9F7R0	Melanoma	2C30	Terminated	[6]
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[11]
FM-101	DMXK6EI	Multiple myeloma	2A83	Investigative	[7]
Sant7	DM9CV4P	Multiple myeloma	2A83	Investigative	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin 6 receptor (IL6R)	TT0E5SK	IL6RA_HUMAN; IL6RB_HUMAN	Antagonist	[4]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] ClinicalTrials.gov (NCT02073279) Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD. U.S. National Institutes of Health.
• [4] IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA. MAbs. 2013 March 1; 5(2): 178-201.
• [5] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2310).
• [8] Pharma & Vaccines. Product Development Pipeline. April 29 2009.
• [9] Clinical pipeline report, company report or official report of Ablynx.
• [10] The preclinical pharmacology of the high affinity anti-IL-6R Nanobody ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015 May 20;17:135.
• [11] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [12] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.